H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $535 from $600 and keeps a Buy rating on the shares after the company announced results from the Phase 2 suzetrigene in lumbosacral radiculopathy. The firm believes Vertex’s plan to continue with the Phase 3 trial with innovative approach to deal with the high placebo response is “scientifically justified.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target lowered to $418 from $509 at Barclays
- Oppenheimer downgrades Vertex after lumbosacral radiculopathy study
- Vertex Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
- Vertex Pharmaceuticals price target lowered to $400 from $451 at RBC Capital
- Vertex Pharmaceuticals price target lowered to $522 from $545 at BofA